Related Experiment Video
Updated: Jun 9, 2026
09:13
Profiling Anti-Neu5Gc IgG in Human Sera with a Sialoglycan Microarray Assay
Published on: July 13, 2017
Serum N-glycan profile shift during human ageing.
Valerie Vanhooren1, Sylviane Dewaele, Claude Libert
1Department for Molecular Biomedical Research, VIB, Gent-Zwijnaarde, Belgium.
Experimental Gerontology
|August 31, 2010
Summary
A novel biomarker, GlycoAgeTest, accurately estimates biological age by analyzing serum N-glycans. This test shows potential for monitoring health, predicting disease, and evaluating anti-aging interventions in humans.
Area of Science:
- Biochemistry
- Gerontology
- Biomarker Discovery
Background:
- Biological age is crucial for understanding and managing age-related diseases.
- Serum N-glycan profiles have been previously linked to aging.
- DNA Sequencer Adapted-Fluorophore Assisted Carbohydrate Electrophoresis (DSA-FACE) is a method for analyzing N-glycans.
Purpose of the Study:
- To validate changes in serum N-glycan profiles during aging.
- To assess the GlycoAgeTest as a biomarker for physiological age.
- To investigate GlycoAgeTest in healthy individuals, dementia patients, and Cockayne syndrome patients.
Main Methods:
- Serum N-glycan profiles were analyzed using DSA-FACE.
- The ratio of NGA2F and NA2F glycans (GlycoAgeTest) was calculated.
- Profiles were compared across different age groups and patient cohorts.
Main Results:
- GlycoAgeTest remained stable until age 40, then increased with age, peaking in nonagenarians.
- Dementia and Cockayne syndrome patients exhibited higher GlycoAgeTest than age-matched controls.
- GlycoAgeTest proved a more accurate estimator of physiological age than chronological age.
Conclusions:
- GlycoAgeTest serves as a reliable biomarker for physiological aging in humans.
- It can be utilized as a non-invasive marker for general health status.
- The test has potential for disease progression forecasting and monitoring anti-aging interventions.
